Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS · MID CAP

Siga Technologies Inc. SIGA

17 fiscal years on record · USD · FY2025 reported · SEC filings only
$94.6M
▼ 31.8% YoY
$23.3M
▼ 60.7% YoY

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

USD 94.6M
Revenue, FY2025 · full 17-year series below
Revenue $M Net income $M
FY2025 · Revenue 94.6 · Net income 23.3
200M400M
2009201220152018202120242025
Compound annual growth
−5.1%
−5.4%
−11.8%
−16.2%
−11.4%
−14.7%
+10.1%
−2.1%
+8.6%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −5.4% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

25 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 25.1% · Net 24.6%
20%40%60%-100%-200%
200920172025
ROE
FY2025 · ROE 11.2%
20%40%-20%-40%-60%
200920172025
Three returns, three denominators.

Each USD of equity produced 11 cents of profit this year.

Cash & shareholders

USD 43.1M
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2019 · FCF -18.2
25.0M50.0M-50.0M-100.0M
200920172025
Net buybacks $M Dividends $M
FY2025 · Dividends 43.1 · Net buybacks 0.0
20M40M-10M-20MDividendsNet buybacks
20092011201520172019202120232025

USD 43.1M in dividends — 185% of the year's profit, so the payout drew on cash built up earlier.

Total assetsUSD 219.5M
EquityUSD 198.8M
CashUSD 155.0M
Current ratio11.83×

Equity funds 91% of total assets.

The 17-year record

17 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
SIGA, 17-year financial record
Metric 20252024202320222021202020192018201720162015201420132012201120102009
Revenue $B0.10.10.10.10.10.10.00.50.00.0◌◌◌◌◌◌◌
Operating income $B0.00.10.10.00.10.1−0.00.4−0.0−0.0−0.0−0.2−0.0−0.0−0.0−0.0−0.0
EBITDA $B0.00.10.10.00.10.1−0.00.4−0.0−0.0−0.0−0.2−0.0−0.0−0.0−0.0−0.0
Income tax $B0.00.00.00.00.00.0−0.0−0.0−0.00.00.00.1−0.0−0.0−0.00.00.0
Net income $B0.00.10.10.00.10.1−0.00.4−0.0−0.0−0.0−0.3−0.0−0.00.0−0.1−0.0
Free cash flow $B◌◌◌◌◌◌−0.00.1−0.0−0.10.00.00.1−0.00.0−0.0−0.0
EPS, diluted $0.320.820.950.460.910.71−0.155.18−0.46−0.69−0.73−4.97−0.33−0.270.09−1.12−0.52
Dividend / sh $0.600.600.450.45◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout %18572479700———————————
ROE %11.228.737.119.745.749.5−7.2—————−76.0−40.7———
Shares out B0.070.070.070.070.070.080.080.080.080.080.080.050.050.050.050.05◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 66 reconciliationsAUDITED

Reconciled in 17 of the 17 fiscal years we could check. Nine checks were skipped: revenue is not tagged before 2016. Six checks were skipped: the balance sheet is not tagged before 2010. Two checks were skipped: EPS is not tagged before 2009.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2009

Share this section

Download image